Drug intelligence / Profile preview

EGFR(V)-EDV-Dox

Development stage: Phase 1
Lead developer: Engeneic
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

EGFR(V)-EDV-Dox is a targeted nanotherapeutic agent developed for the treatment of cancers such as glioblastoma multiforme (GBM). It consists of bacterially derived minicells (EnGeneIC EDV™ technology) that package doxorubicin as a cytotoxic payload. The minicells are approximately 400 nm in size and are engineered to target cancer cells overexpressing epidermal growth factor receptor (EGFR) via bispecific antibodies attached to their surface. This approach aims to deliver high concentrations of chemotherapy directly to tumor cells while minimizing systemic toxicity[1][3][5].

Other names: Doxorubicin-loaded EDV nanocellsDoxorubicin packaged EDV™ nanocells - EnGeneICEnGeneIC Delivery Vehicle™EnGeneIC Dream Vector™

Targets

TOP2A (DNA topoisomerase II)EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on EGFR(V)-EDV-Dox.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EGFR(V)-EDV-Dox.